Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

Published:2020-05-12 Issue:3 Volume:108 Page:487-493
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Serritella Anthony V.¹,Strohbehn Garth W.¹²,Goldstein Daniel A.²³⁴⁵,Lichter Allen S.²,Ratain Mark J.¹²

Affiliation:

1. Department of Medicine The University of Chicago Chicago Illinois USA

2. Value in Cancer Care Consortium Ann Arbor Michigan USA

3. Tel Aviv University Tel Aviv Israel

4. Davidoff Cancer CenterRabin Medical Center Petah Tikva Israel

5. Department of Health Policy and Management Gillings School of Public Health University of North Carolina Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1853

Reference57 articles.

1. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011

2. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Accessed January 31 2020.

3. From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research

4. Redefining the primary objective of phase I oncology trials

5. Potential for value-based prescribing of oral oncology drugs

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

2. Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model;British Journal of Clinical Pharmacology;2024-07-03

3. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system;The Lancet Oncology;2024-06

4. Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer;Clinical Pharmacology & Therapeutics;2024-04-11

5. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review;BMJ Oncology;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3